Study: AstraZeneca Vaccine Greatly Reduces Virus Transmission Rate
2021-02-04
LRC
TXT
大字
小字
滚动
全页
1A new study suggests the Oxford-AstraZeneca COVID-19 vaccine cuts transmission of the virus by two-thirds and prevents severe disease.
2Oxford University released the results on Wednesday.
3The research has not yet been peer reviewed, meaning other scientists have not examined it.
4But, Britain's Health Secretary Matt Hancock told broadcaster Sky News the findings are "very good news."
5Hancock said the latest results showed the AstraZeneca vaccine slows spread of the virus by about 66 percent.
6He added that the study also found the vaccine injections were highly protective after a single dose.
7The head of research and development for AstraZeneca, Mene Pangalos, told reporters no patients had experienced severe disease or hospitalization three weeks after receiving a first dose.
8The effectiveness of the vaccine appeared to increase up to 12 weeks after the first shot, he added.
9The European Medicines Agency approved the vaccine for adults of all ages last week.
10However, most of the subjects involved in the AstraZeneca vaccine trials were under 55 years old.
11Italy and Belgium have approved use of the vaccine in adults under 55.
12Belgium's health minister said there was not enough information available "to be sure to say that it is good" for older individuals.
13Poland is permitting use in adults up to age 60.
14And Germany, Italy, and Sweden have approved its use for people 18 to 65 years old.
15The new Oxford study found that those who were given a single dose of the vaccine were 67 percent less likely to test positive for COVID-19.
16This suggests the possibility "for a substantial reduction in transmission," it said.
17The study provides support for Britain's campaign to treat as many high-risk groups as possible with a first dose of the vaccine.
18The country is providing second injections 12 weeks after the first.
19It argues that the delay will help protect more people quickly.
20Some experts disagree.
21The other vaccine already in use in Britain is from Pfizer-BioNTech.
22That medicine is advised for use in two doses given three weeks apart.
23But, Health Secretary Hancock said Wednesday that Britain believes a 12-week period is the right plan for both vaccines.
24The Oxford study involved more than 17,000 people in Britain, Brazil and South Africa.
25I'm Bryan Lynn.
1A new study suggests the Oxford-AstraZeneca COVID-19 vaccine cuts transmission of the virus by two-thirds and prevents severe disease. Oxford University released the results on Wednesday. 2The research has not yet been peer reviewed, meaning other scientists have not examined it. But, Britain's Health Secretary Matt Hancock told broadcaster Sky News the findings are "very good news." 3Hancock said the latest results showed the AstraZeneca vaccine slows spread of the virus by about 66 percent. He added that the study also found the vaccine injections were highly protective after a single dose. 4The head of research and development for AstraZeneca, Mene Pangalos, told reporters no patients had experienced severe disease or hospitalization three weeks after receiving a first dose. The effectiveness of the vaccine appeared to increase up to 12 weeks after the first shot, he added. 5The European Medicines Agency approved the vaccine for adults of all ages last week. However, most of the subjects involved in the AstraZeneca vaccine trials were under 55 years old. 6Italy and Belgium have approved use of the vaccine in adults under 55. Belgium's health minister said there was not enough information available "to be sure to say that it is good" for older individuals. 7Poland is permitting use in adults up to age 60. And Germany, Italy, and Sweden have approved its use for people 18 to 65 years old. 8The new Oxford study found that those who were given a single dose of the vaccine were 67 percent less likely to test positive for COVID-19. This suggests the possibility "for a substantial reduction in transmission," it said. 9The study provides support for Britain's campaign to treat as many high-risk groups as possible with a first dose of the vaccine. The country is providing second injections 12 weeks after the first. It argues that the delay will help protect more people quickly. Some experts disagree. 10The other vaccine already in use in Britain is from Pfizer-BioNTech. That medicine is advised for use in two doses given three weeks apart. But, Health Secretary Hancock said Wednesday that Britain believes a 12-week period is the right plan for both vaccines. 11The Oxford study involved more than 17,000 people in Britain, Brazil and South Africa. 12I'm Bryan Lynn. 13The Associated Press, Agence France-Presse and VOA News reported on this story. Bryan Lynn adapted the reports for Learning English. Caty Weaver was the editor. 14We want to hear from you. Write to us in the Comments section, and visit our Facebook page. 15_______________________________________________________________ 16Words in This Story 17transmission - n. the process of passing something from one person to another 18dose - n. the amount of something, such as a medicine, that is needed to have the expected result 19positive - adj. in a medical test, positive means the person being tested has a disease or condition